IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved
SUZHOU, China, Dec. 26, 2024 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study…
4 min read